ZyVersa Therapeutics Begins Patient Recruitment for VAR 200
In a significant advancement, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has announced the activation of its first clinical site for the VAR 200 Phase 2a clinical trial. This trial aims to recruit patients suffering from diabetic kidney disease (DKD), marking a pivotal step in the journey towards developing innovative therapies for kidney-related complications.
Importance of VAR 200 in Treating Kidney Disease
VAR 200 represents a potential first-in-class drug specifically addressing renal lipotoxicity, a condition that adversely affects the kidneys' filtration system. Current treatments fail to target this critical pathway, leading to issues such as proteinuria and progressive kidney damage. The Phase 2a clinical trial will evaluate the drug's effectiveness in providing relief from these complications.
Preclinical Data and Future Expectations
Preclinical studies have highlighted VAR 200’s ability to decrease cholesterol and lipid buildup, offering protection against renal injury and fibrosis. The drug has shown promise across various types of kidney disease, including DKD, Focal Segmental Glomerulosclerosis, and Alport Syndrome. In particular, the upcoming Phase 2a study will offer the first proof-of-concept data in humans, which is eagerly anticipated in the coming years.
Collaboration with Experts
Further driving the trial is the involvement of the Clinical Advancement Center, PLLC, located in San Antonio, Texas, and led by Dr. Pablo Pergola. The collaboration aims to develop cutting-edge treatments that can reshape the treatment landscape for patients with kidney diseases. ZyVersa’s Co-founder and CEO, Stephen C. Glover, emphasizes the urgency of addressing kidney lipotoxicity and its role in DKD progression.
Clinical Study Details
The Phase 2a trial is designed as an open-label study spanning 16 weeks, which includes 12 weeks of treatment followed by a four-week follow-up. Patients will receive intravenous administration of VAR 200 twice a week, supplemented alongside their existing medication regimen. The primary efficacy endpoint will focus on the change in urinary albumin to creatinine ratio, a key marker of kidney function.
Understanding Cholesterol Efflux Mediator™ VAR 200
Cholesterol Efflux Mediator™ VAR 200, which is also referred to as 2-hydroxypropyl-beta-cyclodextrin (2HP?CD), is an injectable drug aimed at alleviating the detrimental accumulation of lipids in the kidneys. This unique formulation works both passively and actively to remove excess lipids, showing significant preclinical promise in animal studies.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is dedicated to delivering first-in-class therapeutics to patients with renal and inflammatory diseases. With a robust pipeline of innovative drug candidates, including VAR 200 and an Inflammasome ASC Inhibitor, ZyVersa is committed to meeting the urgent medical needs of patients suffering from conditions that currently have inadequate treatment options. To learn more about their work and developments, individuals are encouraged to visit the company’s website.
Frequently Asked Questions
What is the purpose of the VAR 200 clinical trial?
The VAR 200 clinical trial aims to evaluate the efficacy and safety of the drug in patients with diabetic kidney disease, focusing on its impact on kidney function.
How does VAR 200 work?
VAR 200 potentially works by alleviating renal lipid accumulation and enhancing cholesterol efflux, which are vital in managing kidney health.
Where is the first clinical site located?
The first clinical site is the Clinical Advancement Center, PLLC in San Antonio, Texas.
What are the expected outcomes of this trial?
The trial aims to provide proof-of-concept data demonstrating the effectiveness of VAR 200 in improving kidney-related parameters in patients.
How can patients participate in the trial?
Patients interested in participating should contact the clinical trial site directly for information regarding eligibility and enrollment procedures.
